Friday, 23 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

MOPOLI Stock 9.09% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with MOPOLI (MOP.BR) jumping 9.09% to €240.00 on Thursday, following the last session's downward trend. BEL 20 jumped 1.18% to €4,081.66, following the last session's downward trend on what was an all-around up trend trading session today.

MOPOLI's last close was €220.00, 21.99% under its 52-week high of €282.00.

About MOPOLI

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.7%.

Volatility

MOPOLI's last week, last month's, and last quarter's current intraday variation average was a positive 4.76%, a negative 7.58%, and a positive 9.92%.

MOPOLI's highest amplitude of average volatility was 4.76% (last week), 10.75% (last month), and 9.92% (last quarter).

Moving Average

MOPOLI's value is below its 50-day moving average of €256.84 and under its 200-day moving average of €262.13.

More news about MOPOLI (MOP.BR).

Categories

stockMarket

Tags

Market-Close NowMOP.BRStock PriceClosesStock Market NowEnd of DayPrice UpMarket CloseStock Price UpStock MarketStockMOPOLI
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,426 source documents archived
Query this data → isubstrate.com